Patton Thompson, MD
Pulmonary Disease · Lexington, KYNPI 1851614028
Payments from drug & device makers
Across 229 payments — averaging $33.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Boehringer Ingelheim$738
- GSK$535
- AstraZeneca$369
- Johnson & Johnson$307
- Sanofi$289
- plus $2K from 27 others
What the payments were for
- Travel & lodging$4906%
- Food & beverage$4,12054%
- Education$3,04240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $3,674 |
| Boehringer Ingelheim | 50 | $738 |
| GSK | 31 | $535 |
| AstraZeneca | 24 | $369 |
| Johnson & Johnson(2 entities) | 6 | $307 |
| Sanofi | 17 | $289 |
| Mylan Specialty L.p. | 14 | $236 |
| Regeneron Healthcare Solutions, Inc. | 10 | $219 |
| Grifols USA, LLC | 11 | $198 |
| Genentech USA, Inc. | 10 | $150 |
| Actelion Pharmaceuticals US, Inc. | 5 | $147 |
| Merck | 4 | $145 |
| United Therapeutics Corporation | 5 | $102 |
| Amgen | 4 | $68 |
| Mallinckrodt Hospital Products Inc. | 2 | $63 |
| Gilead | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Sunovion Pharmaceuticals Inc. | 3 | $36 |
| Astellas Pharma US Inc | 2 | $31 |
| Portola Pharmaceuticals, LLC | 1 | $29 |
| Noctrix Health, Inc. | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Edwards Lifesciences | 1 | $25 |
| Electromed, Inc. | 2 | $24 |
| Tactile Systems Technology Inc | 1 | $20 |
| Insmed, Inc. | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| AbbVie | 1 | $15 |
| Mayne Pharma Commercial LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Philips North America LLC | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Inogen, Inc. | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,477
- Monarch Platform$217
- KEYTRUDA$114
How this compares
$7,652 in reported general payments places this provider in the 60th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 216 | $169,300 |
| Dupixent PenDupilumab | 13 | $48,833 |
| Spiriva RespimatTiotropium Bromide | 54 | $28,667 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $26,285 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $17,557 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $13,865 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $10,330 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $8,561 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $6,890 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,189 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $4,586 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $3,519 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 100 | $2,565 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,225 |
| Prednisone | 66 | $415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $535 | $197,186272 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $738 | $51,09398 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $369 | $33,17561 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Lexington
- Girish NairLexington$852K
- Ketan BuchLexington$150K
- Dennis DohertyLexington$103K
- Ashish MaskeyLexington$94K
- John ThompsonLexington$79K
- Said ChaabanLexington$48K
- Mehdi KhosraviLexington$48K
- Parijat SenLexington$26K
- Harish SeethamrajuLexington$26K
- Anthony GerberLexington$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.